SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: guido leone who wrote (1257)9/12/1997 2:21:00 AM
From: Howard Hoffman   of 1762
 
I believe that it means several things. It means that the company is willing to forgo a killing (>45) in exchange for a fat profit and the ability to float shares at 45. This will give them lots of cash for production facilities or acquisitions like the recently announced one. I think that recemt stength in IDPH is due to (1) the realization by the market that this option deal is both bullish itself and a bullish expression by IDPH about its prospects, (2) closing in on FDA approval.

Even though IDPH has sold on the news every time before, I believe that FDA approval of Rituxan should be different. Or at least if IDPH sells initially, it will come back up very quickly. This prediction assumes that the stock has not been bid up too high (like >45) before approval. This prediction is based on a scenario where the approval of Rituxan generates great general media coverage -- national TV, national magazines, etc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News